Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, Mar 10 2020

Full Issue

Gates Foundation, Charitable Groups Launch $125M Effort To Speed Development Of Coronavirus Treatment

One of initiative’s first goals will be to test antiviral drugs that have already gone through preclinical development or have already been tested in humans.

Stat: $125M Effort To Find Coronavirus Drugs Started By Gates Foundation, Wellcome, And Mastercard

The Bill & Melinda Gates Foundation, along with the charitable group Wellcome and Mastercard, announced Tuesday that they were launching a $125 million effort to speed up the development of drugs to treat the novel coronavirus. The initiative, known as the Covid-19 Therapeutics Accelerator, will not be enough to develop even a single new medicine. But Trevor Mundel, the president of the Gates Foundation, said the funding could provide important funds to companies and academic researchers immediately, before government funding will be available. Mundel estimates that two dozen companies, evenly divided between large pharmaceutical firms and small biotechs, could be involved in the effort. (Herper, 3/10)

Reuters: Gates, Other Charities Pledge $125 Million Towards COVID-19 Treatments

The Gates Foundation’s funding is part of its $100 million commitment to the COVID-19 response announced last month. "Viruses like COVID-19 spread rapidly, but the development of vaccines and treatments to stop them moves slowly," Mark Suzman, chief executive officer of the Bill & Melinda Gates Foundation, said in a statement. "If we want to make the world safe from outbreaks like COVID-19, particularly for those most vulnerable, then we need to find a way to make research and development move faster. That requires governments, private enterprise, and philanthropic organizations to act quickly to fund research and development." (Steenhuysen, 3/10)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, June 12
  • Thursday, June 11
  • Wednesday, June 10
  • Tuesday, June 9
  • Monday, June 8
  • Friday, June 5
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF